The Obesity Market Is Still Growing, but the Debate Has Changed The GLP-1 obesity market remains one of the most attractive growth pools in global pharma, but investor debate has shifted
Examples include various types of arthritis, such as osteoarthritis or rheumatoid arthritis
Omega-3 and omega-6 PUFA are incorporated into phospholipids, where they not only serve structural roles in cell membranes of the nervous system, but also affect membrane fluidity, flexibility, permeability, as well as the activities of membrane-associated enzymes and receptors (13, 90)
Glucagon-receptor activation contributes effects on hepatic lipid metabolism and whole-body energy expenditure that are absent from GLP-1 mono-agonists and dual GLP-1/GIP agonists
Other GLP-1 receptor agonists (e.g., liraglutide, dulaglutide, exenatide) : Using multiple GLP-1 drugs together does not increase effectiveness but does increase side effects like nausea, vomiting, and diarrhea
( 10.1097/01.gco.0000192994.37965.c6) [DOI] [PubMed] [Google Scholar] Tsounapi P, Honda M, Dimitriadis F, Koukos S, Hikita K, Zachariou A, Sofikitis N, Takenaka A.2018